70 related articles for article (PubMed ID: 19879136)
1. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.
Zammit SC; Cox AJ; Gow RM; Zhang Y; Gilbert RE; Krum H; Kelly DJ; Williams SJ
Bioorg Med Chem Lett; 2009 Dec; 19(24):7003-6. PubMed ID: 19879136
[TBL] [Abstract][Full Text] [Related]
2. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
3. 3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy.
Williams SJ; Zammit SC; Cox AJ; Shackleford DM; Morizzi J; Zhang Y; Powell AK; Gilbert RE; Krum H; Kelly DJ
Bioorg Med Chem Lett; 2013 Dec; 23(24):6868-73. PubMed ID: 24169234
[TBL] [Abstract][Full Text] [Related]
4. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes.
Jones SE; Gilbert RE; Kelly DJ
J Diabetes Complications; 2004; 18(5):309-15. PubMed ID: 15337505
[TBL] [Abstract][Full Text] [Related]
5. FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy.
Tan SM; Zhang Y; Wang B; Tan CY; Zammit SC; Williams SJ; Krum H; Kelly DJ
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):650-6. PubMed ID: 22612418
[TBL] [Abstract][Full Text] [Related]
6. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
7. Tranilast attenuates chronic cyclosporine nephrotoxicity in rats.
Tao Y; Hu L; Li S; Bai Y; Liu Q; Jin Y; Wei D; Luo Z
Transplant Proc; 2009 Dec; 41(10):4373-5. PubMed ID: 20005402
[TBL] [Abstract][Full Text] [Related]
8. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.
Kelly DJ; Zhang Y; Gow R; Gilbert RE
J Am Soc Nephrol; 2004 Oct; 15(10):2619-29. PubMed ID: 15466266
[TBL] [Abstract][Full Text] [Related]
9. Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy.
Tan SM; Zhang Y; Cox AJ; Kelly DJ; Qi W
Nephrol Dial Transplant; 2011 Jan; 26(1):100-10. PubMed ID: 20573806
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Russo LM; del Re E; Brown D; Lin HY
Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
[TBL] [Abstract][Full Text] [Related]
11. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
12. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction.
Miyajima A; Asano T; Asano T; Yoshimura I; Seta K; Hayakawa M
J Urol; 2001 May; 165(5):1714-8. PubMed ID: 11342962
[TBL] [Abstract][Full Text] [Related]
13. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat.
Gilbert RE; Zhang Y; Williams SJ; Zammit SC; Stapleton DI; Cox AJ; Krum H; Langham R; Kelly DJ
PLoS One; 2012; 7(10):e47160. PubMed ID: 23071743
[TBL] [Abstract][Full Text] [Related]
14. Effect of tranilast in early-stage diabetic nephropathy.
Soma J; Sato K; Saito H; Tsuchiya Y
Nephrol Dial Transplant; 2006 Oct; 21(10):2795-9. PubMed ID: 16820373
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
Lloberas N; Cruzado JM; Franquesa M; Herrero-Fresneda I; Torras J; Alperovich G; Rama I; Vidal A; Grinyó JM
J Am Soc Nephrol; 2006 May; 17(5):1395-404. PubMed ID: 16597691
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
17. Polyphenolic extract of Ichnocarpus frutescens attenuates diabetic complications in streptozotocin-treated diabetic rats.
Kumarappan CT; Mandal SC
Ren Fail; 2008; 30(3):307-22. PubMed ID: 18350451
[TBL] [Abstract][Full Text] [Related]
18. The pyridoindole antioxidant stobadine attenuates albuminuria, enzymuria, kidney lipid peroxidation and matrix collagen cross-linking in streptozotocin-induced diabetic rats.
Stefek M; Gajdosik A; Tribulova N; Navarova J; Volkovova K; Weismann P; Gajdosikova A; Drimal J; Mihalova D
Methods Find Exp Clin Pharmacol; 2002 Nov; 24(9):565-71. PubMed ID: 12616702
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells.
Ikeda H; Inao M; Fujiwara K
Biochem Biophys Res Commun; 1996 Oct; 227(2):322-7. PubMed ID: 8878516
[TBL] [Abstract][Full Text] [Related]
20. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
